Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024 AN2 Therapeutics (NASDAQ: ANTX ) just reported results for the first quarter of 2024. AN2 Therapeutics reported earnings per share of -56 cents. This was above the analyst estimate for EPS of -62 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024 appeared first on InvestorPlace .
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024. “The Phase 2 topline data, expected to be available in August, will include the first clinical efficacy data for epetraborole in patients with treatment-refractory MAC. The patients enrolled in EBO-301.
AN2 Therapeutics stock upgraded by JPM Securities on drug path clarity https://www.investing.com/news/company-news/an2-therapeutics-stock-upgraded-by-jpm-securities-on-drug-path-clarity-93CH-3360978
AN2 Therapeutics’ High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties AN2 Therapeutics, Inc. (ANTX) has disclosed a new risk, in the Innovation / R&D category. AN2 Therapeutics, Inc. faces significant business risk as…
AN2 Therapeutics GAAP EPS of -$0.57 beats by $0.17 AN2 Therapeutics reports Q4 2023 financial results, beating expectations with a GAAP EPS of -$0.57.
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023 AN2 Therapeutics (NASDAQ: ANTX ) just reported results for the fourth quarter of 2023. AN2 Therapeutics reported earnings per share of -57 cents. This was above the analyst estimate for EPS of -76 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023 appeared first on InvestorPlace .
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. “AN2's cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to bel.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. NEW YORK, March 11, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. (“AN2” or the “Company”) (NASDAQ: ANTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether AN2 and certain of its officers and/or directors have engaged in securities fraud or […] The post SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. appeared first on Businessfortnight .